Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08 nov. 2017 16h12 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
08 nov. 2017 16h05 HE
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
01 nov. 2017 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
30 août 2017 07h00 HE
|
Otonomy, Inc.
Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpointsCompany to immediately suspend all development activities for OTIVIDEXCompany is also undertaking a review of its...
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
03 août 2017 16h12 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
27 juil. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa
18 juil. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
22 juin 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
20 juin 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference
10 mai 2017 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...